RecruitingPhase 3NCT06982521Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerSponsor: Relay Therapeutics, Inc.Austin, TX · Dallas, TX · +49 more sites
RecruitingPhase 3NCT05812807Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabSponsor: Alliance for Clinical Trials in OncologyBaytown, TX · Conroe, TX · Cypress, TX · +825 more sites
RecruitingPhase not listedNCT07327489Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)Sponsor: ElephasForth Worth, TX · Temple, TX · +6 more sites